Phase II Study of Single-agent Pazopanib (Votrient) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).

Trial Profile

Phase II Study of Single-agent Pazopanib (Votrient) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Germ cell and embryonal neoplasms; Seminoma
  • Focus Therapeutic Use
  • Acronyms Pazotest-01
  • Most Recent Events

    • 05 Apr 2017 Results assessing safety and efficacy, published in the Annals of Oncology
    • 18 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 18 Feb 2017 Final results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top